Шлевков Н. Б., Бакалов С. А., Паша С. П., Сергакова Л. М., Нестеренко Л. Ю., Сергиенко В. Б., Голицын С. П. ПОКАЗАТЕЛИ СОКРАТИМОСТИ СЕГМЕНТОВ МИОКАРДА ЛЕВОГО ЖЕЛУДОЧКА, СООТВЕТСТВУЮЩИХ ТОПОГРАФИИ АРИТМОГЕННЫ1Х ЗОН, - ВЫСОКОСПЕЦИФИЧНЫЕ МАРКЁРЫ РЕЗУЛЬТАТОВ ТЕСТИРОВАНИЯ АНТИАРИТМИЧЕСКИХ ПРЕПАРАТОВ У БОЛЬНЫХ ПАРОКСИЗМАЛЬНЫМИ ЖЕЛУДОЧКОВЫМИ ТАХИКАРДИЯМИ. Вестник аритмологии. 2007;(49):14-24.
1. Cheng W, Li B, Kajstura О, Li P, Wolin MS et al. Stretch-induced programmed myocyte cell death. // J Clin. Invest. 1995; 96: 2247-2259.
2. Chinushi M, Aizawa Y, Miyajima S, Funazaki T, Tamura M, Shibata A. Proarrhythmic effects of antiarrhythmic drugs assessed by electrophysiologic study in recurrent sustained ventricular tachycardia. // Jpn Circ J. 1991; 55: 133-141.
3. Costeas XF, Link MS, Foote CB, et al. Predictors of ventricular tachycardia recurrence in 100 patients receiving tiered therapy defibrillators. // Clin Cardiol 2000; 23:852-856.
4. Hallstrom AP, McAnulty JH, Wilkoff BL, et al. Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial Investigators. Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit. Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial Investigators. // JACC 2001; 37: 1093-1099.
5. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. // Physiological Review, 1989; 69: 1049-1149.
6. Josephson ME. Clinical cardiac electrophysiology: Technique and interpretation. 1993, Lea and Febiger // Chapter 14, Evaluation of antiarrhythmic agents, pages: 630-683.
7. Josephson ME. Clinical cardiac electrophysiology: Technique and interpretation. 2-nd edition. 1993 Lea and Febiger // Chapter 12, Recurrent ventricular tachycardia, pages: 417-616.
8. Josephson ME, Callans DJ. Using the twelve-lead electrocardiogram to localize the site of origin of ventricular tachycardia. // Heart Rhythm 2005;2:443-446.
9. Kuchar DL, Ruskin JN, Garan H. “Electrocardiographic localization of the site of origin of ventricular tachycardia in patients with prior myocardial infarction.” // J Am Coll Cardiol. 1989;13:893-903.
10. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). // Circulation. 2000;102:748-754.
11. Lab MJ. Mechanoelectric feedback (transduction) in heart: concepts and implications. // Cardiovasc Res 1996; 32:3-14.
12. Moss AJ. Everyone with an ejection fraction less than or equal to 30 % should receive an implantable cardiverter-defibrillator. // Circulation 2005;111:2542-2549.
13. Sheldon R, Connoly S, Krahn A, et al. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. // Circulation 2000;101:1660-1664.
14. Steinbeck G, Haberl R, Hoffman E. Management of patients with life-threating ventricular tachyarrhythmias in the defibrillator era: the need to differentiate. // PACE 1997;20:2719-2724.
15. Sweeney MO. Sudden death in heart failure associated with reduced left ventricular function: substrates, mechanisms, and evidence-based management, Part I. // Pacing Clin Electrophysiol. 2001;24:871-888.
16. Van Hemel NM, Kingma JH, Defauw JA, et al. Left ventricular segmental wall motion score as a criterion for selecting patients for direct surgery in the treatment of postinfarction ventricular tachycardia. // European Heart J 1989;10:304-315.
17. Watanabe H, Chinushi M, Washizuka, et al. Electrophysiologic study-guided therapy with sotalol for life threatening ventricular tachyarrhthmias // PACE, 2005;28:285-290.
